CL2014001081A1 - Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica. - Google Patents

Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica.

Info

Publication number
CL2014001081A1
CL2014001081A1 CL2014001081A CL2014001081A CL2014001081A1 CL 2014001081 A1 CL2014001081 A1 CL 2014001081A1 CL 2014001081 A CL2014001081 A CL 2014001081A CL 2014001081 A CL2014001081 A CL 2014001081A CL 2014001081 A1 CL2014001081 A1 CL 2014001081A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
antibodies
antibody
vector
host cell
Prior art date
Application number
CL2014001081A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Garidel
Isaac Craig Henderson
Pamela Klein
Original Assignee
Onclave Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onclave Therapeutics Ltd filed Critical Onclave Therapeutics Ltd
Publication of CL2014001081A1 publication Critical patent/CL2014001081A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
CL2014001081A 2011-10-25 2014-04-25 Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica. CL2014001081A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551406P 2011-10-25 2011-10-25

Publications (1)

Publication Number Publication Date
CL2014001081A1 true CL2014001081A1 (es) 2014-11-21

Family

ID=48168501

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014001081A CL2014001081A1 (es) 2011-10-25 2014-04-25 Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica.
CL2017002283A CL2017002283A1 (es) 2011-10-25 2017-09-08 Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017002283A CL2017002283A1 (es) 2011-10-25 2017-09-08 Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)

Country Status (19)

Country Link
US (6) US20140302021A1 (OSRAM)
EP (2) EP4088736A1 (OSRAM)
JP (6) JP6431372B2 (OSRAM)
KR (2) KR102196009B1 (OSRAM)
CN (2) CN107233569B (OSRAM)
AU (4) AU2012328739B2 (OSRAM)
BR (1) BR112014009866A2 (OSRAM)
CA (1) CA2853112C (OSRAM)
CL (2) CL2014001081A1 (OSRAM)
CO (1) CO7020867A2 (OSRAM)
EA (1) EA037797B1 (OSRAM)
HK (1) HK1198689A1 (OSRAM)
IL (1) IL232213B (OSRAM)
IN (1) IN2014CN03555A (OSRAM)
MX (2) MX354988B (OSRAM)
PE (2) PE20141413A1 (OSRAM)
PH (1) PH12014500904B1 (OSRAM)
SG (2) SG11201401360XA (OSRAM)
WO (1) WO2013063284A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141568A1 (es) 2011-10-28 2014-11-21 Neotope Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleina
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
US10793622B2 (en) * 2013-05-06 2020-10-06 Sanofi Continuous multistep process for purifying antibodies
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SI3478713T1 (sl) * 2016-06-30 2022-06-30 Prothena Biosciences Limited Sestavki za zdravljenje amiloidoze
EP3605294A4 (en) 2017-03-23 2020-02-26 Sony Corporation RADIATION RADIATION DEVICE AND PROJECTOR WITH DETECTION FUNCTION
KR20230164223A (ko) 2017-06-29 2023-12-01 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 아밀로이드 침착 질환의 치료를 위한 키메라 항체
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
CN112040983A (zh) * 2018-03-23 2020-12-04 普罗西纳生物科学有限公司 淀粉样变性的治疗和预防
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
CN119950702A (zh) 2019-02-12 2025-05-09 普罗塞纳生物科学有限公司 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
JP7619953B2 (ja) 2019-03-05 2025-01-22 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法
GB202507045D0 (en) * 2022-10-12 2025-06-25 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682047D1 (de) 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
EP0663826B1 (en) 1991-09-27 1998-12-23 Board Of Regents The University Of Texas System Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
US5334380A (en) 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
CA2127877A1 (en) 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
WO1993015736A1 (en) 1992-02-18 1993-08-19 Pharmos Corp. Dry compositions for preparing submicron emulsions
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
NZ262634A (en) 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
DE69434626D1 (de) 1993-11-17 2006-04-20 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5952004A (en) 1994-03-18 1999-09-14 Shire Laboratories Inc. Emulsified drug delivery systems
JP4142095B2 (ja) 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
ES2208687T3 (es) 1994-08-04 2004-06-16 Elan Drug Delivery Limited Sistema de administracion de sustancias solidas para la liberacion controlada de moleculas incorporadas en tales sustancias y procedimientos para la fabricacion de tales sistemas.
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5593824A (en) 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
EP0831790B1 (en) 1995-06-07 2003-05-07 Elan Drug Delivery Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
EP1516628B1 (en) * 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
USRE38431E1 (en) 1995-12-01 2004-02-17 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9705588D0 (en) 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
EP0996423B1 (en) 1997-04-03 2011-06-08 Elias Hakalehto A method for producing jelly sweets which contain antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
EP1028712B1 (en) 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
KR100652943B1 (ko) 1998-06-26 2006-12-01 오츠카 세이야쿠 가부시키가이샤 수용성 건조 조성물
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
IL142432A0 (en) 1998-10-05 2002-03-10 Penn State Res Found Compositions and methods for enhancing receptor-mediated cellular internalization
CA2347856C (en) 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
PT1666026E (pt) 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ATE244558T1 (de) 1999-04-16 2003-07-15 Novo Nordisk As Trockene formbare arzneistoffformulierung
CA2370853C (en) 1999-05-03 2007-07-10 Battelle Memorial Institute Compositions for aerosolization and inhalation
HK1043312B (en) 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
GB9914412D0 (en) 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
KR100771294B1 (ko) 1999-12-14 2007-10-29 써모 바이오스타, 인크. 폴리펩티드 및 항원 안정화 희석제
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
TR201900581T4 (tr) 2001-06-26 2019-02-21 Amgen Fremont Inc Opgl ye karşı antikorlar.
US6646394B2 (en) * 2001-07-09 2003-11-11 Nissan Motor Co., Ltd. Control device for plurality of rotating electrical machines
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
EP1475100B1 (en) 2002-02-14 2015-05-06 Chugai Seiyaku Kabushiki Kaisha Use of acetic acid for suppressing Fe ion induced problems in formulations of anti-HM1.24 or anti-IL6R antibodies
ATE402716T1 (de) 2002-02-27 2008-08-15 Immunex Corp Stabilisierte tnfr-fc formulierung mit arginin
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
JP2006516084A (ja) * 2002-06-27 2006-06-22 セントカー・インコーポレーテツド Ｃｎｇｈ０００４ポリペプチド、抗体、組成物、方法および使用
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
LT2395073T (lt) 2002-11-01 2017-11-10 Glaxosmithkline Biologicals S.A. Džiovinimo būdas
CA2504610C (en) 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2508592A1 (en) 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
PT2335725T (pt) 2003-04-04 2017-01-06 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
WO2004110498A2 (en) 2003-05-14 2004-12-23 Immunogen, Inc. Drug conjugate composition
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
SI1682178T1 (sl) 2003-11-04 2010-11-30 Novartis Vaccines & Diagnostic Postopki za terapijo raka ob eksprimiranju CD antigena
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
SI21639A (sl) 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
AU2005226736B2 (en) 2004-03-24 2009-11-26 Abbvie Biotherapeutics Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
GB0409795D0 (en) 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005306997B2 (en) * 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
EP1827373B1 (en) 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
US20060124266A1 (en) * 2004-11-23 2006-06-15 Novozymes North America, Inc. Use of cyclodextrins for reducing deposits during paper production
US7897585B1 (en) 2005-01-04 2011-03-01 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7879313B1 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7919072B1 (en) 2005-01-04 2011-04-05 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7910086B1 (en) 2005-01-04 2011-03-22 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8048453B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
US7993625B1 (en) 2005-01-04 2011-08-09 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
MY139088A (en) 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
JP4890537B2 (ja) 2005-04-18 2012-03-07 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 安定化抗ｂ型肝炎ウイルス（ｈｂｖ）抗体製剤
HRP20110334T1 (hr) 2005-04-22 2011-06-30 Eli Lilly And Company PROTUTIJELA SPECIFIČNA ZA TGF-ß1
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
US8067547B2 (en) 2005-06-07 2011-11-29 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting TNFα
WO2007005608A2 (en) 2005-06-30 2007-01-11 Abbott Laboratories Il-12/p40 binding proteins
ES2390354T3 (es) 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
ATE517923T1 (de) * 2005-12-12 2011-08-15 Hoffmann La Roche Antikörper gegen amyloid beta mit glykosilierung in der variablen region
CA2634131C (en) 2005-12-21 2014-02-11 Wyeth Protein formulations with reduced viscosity and uses thereof
PL2004688T5 (pl) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
DE102006030164A1 (de) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
GB0621707D0 (en) 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
MX2009005414A (es) 2006-12-05 2009-06-01 Crucell Holland Bv Formulaciones liquidas de anticuerpo antirrabico.
TW200831133A (en) * 2006-12-11 2008-08-01 Hoffmann La Roche Mab Abeta lyophylized formulation
US7883664B2 (en) 2007-06-27 2011-02-08 University Of North Carolina At Charlotte Microwave drying process for vitrification of biologics
US8268354B2 (en) 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
CA2708869C (en) 2007-12-21 2016-06-28 F. Hoffmann-La Roche Ag Antibody formulation
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009086539A2 (en) * 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
SG2014011365A (en) 2008-09-19 2014-05-29 Hoffmann La Roche Novel antibody formulation
EP2358393A1 (en) * 2008-11-20 2011-08-24 F.Hoffmann-La Roche Ag Therapeutic protein formulations
CN201401081Y (zh) 2009-03-26 2010-02-10 徐谦 一种两折型合页
CN201553504U (zh) * 2009-10-30 2010-08-18 浙江浦江缆索有限公司 一种悬索拉索成圈用120t成圈机
CA2939204C (en) * 2014-03-14 2023-06-27 Innate Pharma Humanized antibodies with increased stability

Also Published As

Publication number Publication date
AU2012328739A1 (en) 2014-04-24
US20210077407A1 (en) 2021-03-18
HK1198689A1 (en) 2015-05-29
PH12014500904A1 (en) 2014-06-09
US20150344555A1 (en) 2015-12-03
MX2014004786A (es) 2014-08-21
PE20141413A1 (es) 2014-10-25
PH12014500904B1 (en) 2019-01-18
AU2022202649A1 (en) 2022-05-12
IN2014CN03555A (OSRAM) 2015-07-03
JP2018184478A (ja) 2018-11-22
US9884020B2 (en) 2018-02-06
EA037797B1 (ru) 2021-05-21
AU2022202649B2 (en) 2025-07-03
MX391043B (es) 2025-03-21
US10517830B2 (en) 2019-12-31
BR112014009866A2 (pt) 2018-09-04
EP2771029A1 (en) 2014-09-03
CL2017002283A1 (es) 2018-05-18
US20160310430A1 (en) 2016-10-27
JP2022033254A (ja) 2022-02-28
KR102196009B1 (ko) 2021-01-04
US20180235887A1 (en) 2018-08-23
CA2853112A1 (en) 2013-05-02
JP6431372B2 (ja) 2018-11-28
AU2017258950A1 (en) 2017-11-30
AU2020201147A1 (en) 2020-03-05
SG11201401360XA (en) 2014-05-29
US9089529B2 (en) 2015-07-28
KR20140123475A (ko) 2014-10-22
IL232213A0 (en) 2014-06-30
EP2771029A4 (en) 2015-07-01
PE20191242A1 (es) 2019-09-16
JP2020063307A (ja) 2020-04-23
CA2853112C (en) 2018-08-21
JP2017057218A (ja) 2017-03-23
HK1243344A1 (zh) 2018-07-13
JP2014530917A (ja) 2014-11-20
CN107233569A (zh) 2017-10-10
CN107233569B (zh) 2021-08-31
CN104023743A (zh) 2014-09-03
WO2013063284A1 (en) 2013-05-02
SG10201604104PA (en) 2016-07-28
CN104023743B (zh) 2017-05-03
EA201490850A1 (ru) 2015-03-31
JP2023116817A (ja) 2023-08-22
KR20210003928A (ko) 2021-01-12
MX354988B (es) 2018-03-28
NZ623606A (en) 2015-12-24
IL232213B (en) 2019-03-31
CO7020867A2 (es) 2014-08-11
AU2012328739B2 (en) 2017-11-30
EP4088736A1 (en) 2022-11-16
KR102276161B1 (ko) 2021-07-14
US20130295082A1 (en) 2013-11-07
US20140302021A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CL2014001081A1 (es) Formulacion farmaceutica que comprende una versión quimérica humanizada del anticuerpo 2a4; vector y celula hospedera que comprenden dichos anticuerpos; metodo para producir formulación farmacéutica.
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
HUS2000056I1 (hu) ANTI-PD-L1 ellenanyagok és alkalmazásaik
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
CL2013003043A1 (es) Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune.
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CL2014000958A1 (es) Polipeptidos de anticuerpos que antagonizan cd4ol; acido nucleico que codifica dicho anticuerpo; vector y célula huesped que la comprenden; composicion farmacéutica; uso de dichos polipéptidos para tratar enfermedad inmunitaria.
CO7010785A2 (es) Anticuerpos específicos para trop-2 y sus usos
HRP20190243T1 (hr) Priprema konjugata antitijela majtanzinoida postupkom s jednim korakom
CO6801647A2 (es) Formulación para anticuerpo anti-α4β7
CO6801648A2 (es) Formulación para anticuerpo anti-α4β7
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
IL249195B (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
HUE044591T2 (hu) Anti-CD40 antitestek és alkalmazásuk
UY34404A (es) Anticuerpo estable unido a múltiples antígenos
CL2014000888A1 (es) Anticuerpos anti-htra1; acido nucleico que codifica dicho anticuerpo; célula anfitriona; metodo para producir dicho anticuerpo; uso para tratar degeneración macular.
CL2013001975A1 (es) Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta.
CL2014000670A1 (es) Cierre para botellas que comprende una composicion de polietileno bimodal; proceso para la preparacion del cierre; proceso para preparar una composicion de polietileno; y composicion de polietileno bimodal.
CO6980627A2 (es) Anticuerpos anti-pfh-tau y sus usos
DK3842456T3 (da) Monoklonalt Interleukin-31-antistof
CL2014000204A1 (es) Construcción de unión de antígeno que comprende dos anticuerpos de dominio (dabs) separados por una región fc; metodo para construir dicha construcción.
HRP20180858T1 (hr) Protutijela koja se vežu na ox40 i njihove uporabe
BR112014013034A2 (pt) método para produzir um anticorpo
DK3275892T3 (da) Præfusions-rsv-f-antigener